← All trials
NCT06952452
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 18, 2022
- Primary completion
- Jul 31, 2026
- Completion date
- Jul 31, 2026
- First posted
- Apr 30, 2025
- Last posted
- Nov 20, 2025
- Enrollment
- 630
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Institut Hospital del Mar d'Investigacions MèdiquesLead sponsor
- Universidad Carlos III MadridCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.